Capricor Therapeutics (CAPR): Reports HOPE-3 Extension Results

Why it is trending

Capricor reported additional HOPE-3 open-label extension findings for deramiocel in Duchenne muscular dystrophy. Participants who switched from placebo to treatment had a 76% reduction in their modeled rate of upper-limb decline compared with their own prior year. The extension analyses were exploratory and do not establish a new placebo-controlled result. The findings were included in the company’s amended FDA application; deramiocel remains investigational and unapproved.

Sector

Healthcare, focused on biotechnology. Capricor develops cell and exosome-based treatments for rare diseases, led by deramiocel for Duchenne muscular dystrophy.

Recent earnings

For Q2 2026, Capricor reported no revenue and a net loss of $40.7 million, or $0.70 per share, compared with a $25.9 million loss, or $0.57 per share, a year earlier. Cash, cash equivalents and marketable securities totaled $237.9 million at quarter-end.

ATA Auto Trend Indicator Review

Capricor’s current small green daily dots show BUY signals, while its larger black weekly dots show SELL signals. The timeframes are mixed, with the weekly SELL representing the dominant trend. Both current bars are still forming, so these signals can change. The latest completed daily signal was BUY and the latest completed weekly signal was SELL. Earlier changes between green and black dots are historical.

Our proprietary ATA Auto Trend Indicator makes these signals easy to follow: small dots track daily buys and sells, while larger dots track weekly buys and sells. Green means buy; black means sell. The weekly timeframe represents the dominant trend. This clear visual approach helps you compare daily and weekly signals and support a more disciplined trading process.

WE PREPARE FOR THE NEXT MOVE RATHER THAN PREDICT IT.

Wednesday October 07, 2026